These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 12917967)

  • 41. Controlled trial of prescribed heroin in the treatment of opioid addiction.
    March JC; Oviedo-Joekes E; Perea-Milla E; Carrasco F;
    J Subst Abuse Treat; 2006 Sep; 31(2):203-11. PubMed ID: 16919749
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Alpha2 adrenergic agonists for the management of opioid withdrawal.
    Gowing L; Farrell M; Ali R; White J
    Cochrane Database Syst Rev; 2003; (2):CD002024. PubMed ID: 12804419
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Does heroin-assisted treatment reduce crime? A review of randomized-controlled trials.
    Smart R; Reuter P
    Addiction; 2022 Mar; 117(3):518-531. PubMed ID: 34105206
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prescription of heroin to treatment resistant heroin addicts: Dutch heroin trials show retention is better with methadone alone.
    Caplehorn J
    BMJ; 2004 Jan; 328(7433):228-9; author reply 229. PubMed ID: 14739202
    [No Abstract]   [Full Text] [Related]  

  • 45. Decision aids for people facing health treatment or screening decisions.
    O'Connor AM; Bennett CL; Stacey D; Barry M; Col NF; Eden KB; Entwistle VA; Fiset V; Holmes-Rovner M; Khangura S; Llewellyn-Thomas H; Rovner D
    Cochrane Database Syst Rev; 2009 Jul; (3):CD001431. PubMed ID: 19588325
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Outcome of long-term heroin-assisted treatment offered to chronic, treatment-resistant heroin addicts in the Netherlands.
    Blanken P; Hendriks VM; van Ree JM; van den Brink W
    Addiction; 2010 Feb; 105(2):300-8. PubMed ID: 19922517
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Retention in methadone maintenance drug treatment for prescription-type opioid primary users compared to heroin users.
    Banta-Green CJ; Maynard C; Koepsell TD; Wells EA; Donovan DM
    Addiction; 2009 May; 104(5):775-83. PubMed ID: 19344438
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Oral naltrexone maintenance treatment for opioid dependence.
    Minozzi S; Amato L; Vecchi S; Davoli M; Kirchmayer U; Verster A
    Cochrane Database Syst Rev; 2006 Jan; (1):CD001333. PubMed ID: 16437431
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cost utility analysis of co-prescribed heroin compared with methadone maintenance treatment in heroin addicts in two randomised trials.
    Dijkgraaf MG; van der Zanden BP; de Borgie CA; Blanken P; van Ree JM; van den Brink W
    BMJ; 2005 Jun; 330(7503):1297. PubMed ID: 15933353
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Slow release oral morphine versus methadone for the treatment of opioid use disorder.
    Klimas J; Gorfinkel L; Giacomuzzi SM; Ruckes C; Socías ME; Fairbairn N; Wood E
    BMJ Open; 2019 Apr; 9(4):e025799. PubMed ID: 30944135
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prescription of heroin for the management of heroin dependence: current status.
    Lintzeris N
    CNS Drugs; 2009; 23(6):463-76. PubMed ID: 19480466
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacological therapies for maintenance treatments of opium dependence.
    Rahimi-Movaghar A; Amin-Esmaeili M; Hefazi M; Yousefi-Nooraie R
    Cochrane Database Syst Rev; 2013 Jan; (1):CD007775. PubMed ID: 23440817
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Dutch research on the effectiveness of medical prescription of heroin; background, research design and preliminary results].
    van den Brink W; Hendriks VM; Blanken P; van Ree JM
    Ned Tijdschr Geneeskd; 2000 Jan; 144(3):108-12. PubMed ID: 10674115
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Psychological and/or educational interventions for the prevention of depression in children and adolescents.
    Merry S; McDowell H; Hetrick S; Bir J; Muller N
    Cochrane Database Syst Rev; 2004; (1):CD003380. PubMed ID: 14974014
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Alpha2 adrenergic agonists for the management of opioid withdrawal.
    Gowing L; Farrell M; Ali R; White J
    Cochrane Database Syst Rev; 2004 Oct; (4):CD002024. PubMed ID: 15495025
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Heroin-assisted treatment for opioid dependence: randomised controlled trial.
    Haasen C; Verthein U; Degkwitz P; Berger J; Krausz M; Naber D
    Br J Psychiatry; 2007 Jul; 191():55-62. PubMed ID: 17602126
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effectiveness of opiate substitution treatment in reducing HIV risk behaviors among African, Caribbean, and Black people: a systematic review.
    Nguemo Djiometio JB; Buzuayew A; Mohamud H; Njoroge I; Kahan M; Nelson LE
    JBI Evid Synth; 2021 Aug; 19(8):1887-1914. PubMed ID: 33851941
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Oral naltrexone maintenance treatment for opioid dependence.
    Minozzi S; Amato L; Vecchi S; Davoli M; Kirchmayer U; Verster A
    Cochrane Database Syst Rev; 2011 Apr; 2011(4):CD001333. PubMed ID: 21491383
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cost-effectiveness of hydromorphone for severe opioid use disorder: findings from the SALOME randomized clinical trial.
    Bansback N; Guh D; Oviedo-Joekes E; Brissette S; Harrison S; Janmohamed A; Krausz M; MacDonald S; Marsh DC; Schechter MT; Anis AH
    Addiction; 2018 Jul; 113(7):1264-1273. PubMed ID: 29589873
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.